InspireMD logo

InspireMDNASDAQ: NSPR

Profile

Sector:

Healthcare

Country:

Israel

IPO:

12 April 2011

Next earnings report:

06 March 2025

Last dividends:

N/A

Next dividends:

N/A
$65.21 M
-27%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector
-63%vs. 3y high
52%vs. sector
-35%vs. 3y high
77%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:34:58 GMT
$2.50+$0.04(+1.63%)

Dividend

No data over the past 3 years
$1.81 M$1.83 M
$1.81 M-$7.89 M

Analysts recommendations

Institutional Ownership

NSPR Latest News

InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates
zacks.com12 November 2024 Sentiment: POSITIVE

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.15 per share a year ago.

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com08 November 2024 Sentiment: POSITIVE

MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
globenewswire.com15 October 2024 Sentiment: POSITIVE

MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved.

NSPR Stock Declines Despite PMA Application Submission for CGuard
zacks.com17 September 2024 Sentiment: NEUTRAL

InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
globenewswire.com16 September 2024 Sentiment: POSITIVE

PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com06 August 2024 Sentiment: POSITIVE

- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial –

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
globenewswire.com05 August 2024 Sentiment: POSITIVE

CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today congratulated the lead investigators on the completion of enrollment in the CREST-2 (Carotid Revascularization Endarterectomy or Stenting Trial) clinical trials. The CGuard carotid stent, utilizing its proprietary MicroNet™ mesh, was included as a device option for stenting in the CREST-2 trials following FDA approval of InspireMD's Investigational Device Exemption (IDE) supplement application in February 2022.

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
globenewswire.com28 May 2024 Sentiment: POSITIVE

Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript
Seeking Alpha14 May 2024 Sentiment: POSITIVE

InspireMD Inc. (NASDAQ:NSPR) will be hosting their Q1 2024 Results Conference Call on May 14, 2024 at 8:30 AM ET. Present on the call will be Chuck Padala, Marvin Slosman, and Craig Shore. Participants on the call include Adam Maeder from Piper Sandler. Welcome to the InspireMD First Quarter 2024 Earnings Call. Please note that all participants are currently in listen-only mode.

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewsWire03 April 2024 Sentiment: POSITIVE

TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.

What type of business is InspireMD?

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

What sector is InspireMD in?

InspireMD is in the Healthcare sector

What industry is InspireMD in?

InspireMD is in the Medical Devices industry

What country is InspireMD from?

InspireMD is headquartered in Israel

When did InspireMD go public?

InspireMD initial public offering (IPO) was on 12 April 2011

What is InspireMD website?

https://www.inspiremd.com

Is InspireMD in the S&P 500?

No, InspireMD is not included in the S&P 500 index

Is InspireMD in the NASDAQ 100?

No, InspireMD is not included in the NASDAQ 100 index

Is InspireMD in the Dow Jones?

No, InspireMD is not included in the Dow Jones index

When was InspireMD the previous earnings report?

No data

When does InspireMD earnings report?

The next expected earnings date for InspireMD is 06 March 2025